Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday. The brokerage presently has a $4.25 price objective on the biopharmaceutical company’s stock. Zacks Investment Research’s target price indicates a potential upside of 20.74% from the company’s previous close.
According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “
Separately, Wedbush reaffirmed a “neutral” rating and issued a $4.00 price objective on shares of Tetraphase Pharmaceuticals in a research report on Monday, June 20th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $9.15.
Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at 3.52 on Tuesday. The firm has a 50-day moving average price of $3.80 and a 200-day moving average price of $4.26. The firm’s market cap is $129.18 million. Tetraphase Pharmaceuticals has a 52-week low of $3.12 and a 52-week high of $12.45.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.47) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.46) by $0.01. The business earned $1.20 million during the quarter, compared to analysts’ expectations of $2.05 million. Tetraphase Pharmaceuticals had a negative net margin of 821.25% and a negative return on equity of 35.43%. Tetraphase Pharmaceuticals’s revenue for the quarter was down 63.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.72) EPS. Analysts predict that Tetraphase Pharmaceuticals will post ($1.98) EPS for the current fiscal year.
A number of large investors have recently bought and sold shares of the stock. Bellevue Group AG purchased a new stake in Tetraphase Pharmaceuticals during the first quarter worth about $102,000. Teton Advisors Inc. purchased a new stake in Tetraphase Pharmaceuticals during the second quarter worth about $103,000. Parametric Portfolio Associates LLC purchased a new stake in Tetraphase Pharmaceuticals during the second quarter worth about $128,000. ProShare Advisors LLC increased its stake in Tetraphase Pharmaceuticals by 1.2% in the second quarter. ProShare Advisors LLC now owns 31,696 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 383 shares during the period. Finally, Nisa Investment Advisors LLC increased its stake in Tetraphase Pharmaceuticals by 2,618.8% in the second quarter. Nisa Investment Advisors LLC now owns 43,500 shares of the biopharmaceutical company’s stock worth $187,000 after buying an additional 41,900 shares during the period. 59.41% of the stock is owned by hedge funds and other institutional investors.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections.